ProQR Therapeutics Announces Results For The Second Quarter Of 2017

LEIDEN, the Netherlands, Aug. 16, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced results for the second quarter of 2017.

“I am pleased with the numerous advancements our team has made this quarter in expanding the depth and breadth of our pipeline with the goal of developing medicines for patients in need,“ said Daniel de Boer, Chief Executive Officer of ProQR. “We have made significant progress in all of our programs as well as in our innovation efforts. Our QR-010 program for CF has completed enrollment of the Phase 1b trial and we look forward to announcing the results from this study in September. Furthermore, for the first program in our ophthalmology pipeline, QR-110 for LCA 10, the FDA and EMA have cleared the IND and CTA, enabling us to start a clinical trial in children and adults to study safety and efficacy. QR-110 was also granted Fast Track designation by the FDA underlining the need for therapeutics for these patients. Additionally, two other programs in our ophthalmology pipeline continue to generate exciting pre-clinical data in Usher syndrome including our QRX-411, which recently was granted orphan drug designation. Our QR-313 program for dystrophic epidermolysis bullosa (DEB) is also progressing in IND-enabling development, on track to start and complete a clinical trial in 2018. Beyond that, we are excited about the Axiomer® platform technology we announced at our R&D day. I’m proud of our scientific team to have invented such a groundbreaking scientific technology that holds the potential to bring a large number of new therapeutics to patients in need.”

Back to news